2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
5
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Lung Neoplasms
3
Solid Tumors
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Insulin-Like Growth Factor I, Resistance To
1
Fallopian Tube Neoplasms
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
ganitumab
3
Paclitaxel
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
tislelizumab
1
teprotumumab
1
dalotuzumab
1
conatumumab
1
cixutumumab
1
Sorafenib
1
Receptor Protein-Tyrosine Kinases
1
Lapatinib
1
Istiratumab
1
Cisplatin
1
Carboplatin
1
Capecitabine
1
BIIB022
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Insulin-Like Growth Factor I, Resistance To
×
dalotuzumab
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled